Hair loss news

Posts

Alopecia Clinical Trials Review

Alopecia Clinical Trials Review

Global Alopecia Clinical Trials Review

The “Alopecia – Global Clinical Trials Review, H2, 2021” clinical trials have been added to the ResearchAndMarkets offering.

The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides prominent drugs for in-progress trials (based on a number of ongoing trials).

The report enhances the decision-making capabilities and helps to create an effective counter-strategies to gain a competitive advantage.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with the reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to Buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Key Topics Covered:

  • Report Guidance
  • The Publisher’s Clinical Trials Report Coverage
  • Clinical Trials by Region
  • Clinical Trials and Average Enrollment by Country
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
  • Top Five Countries Contributing to Clinical Trials in Europe
  • Top Countries Contributing to Clinical Trials in North America
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
  • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Alopecia to Dermatology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Alopecia to Dermatology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
  • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
  • Top Companies Participating in Alopecia Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profile Snapshots
  • Appendix

Companies Mentioned

  • Pfizer Inc
  • Concert Pharmaceuticals Inc
  • Johnson & Johnson
  • AbbVie Inc
  • Aclaris Therapeutics Inc
  • Cosmo Pharmaceuticals NV
  • Dr. Reddy’s Laboratories Ltd
  • Almirall SA
  • Applied Biology Inc
  • GlaxoSmithKline Plc

For more information about this clinical trials report visit https://www.researchandmarkets.com

Global Alopecia Clinical Trials Review

Source

Recent Posts

Alopecia Clinical Trials Review

Alopecia Clinical Trials Review

Global Alopecia Clinical Trials Review

The “Alopecia – Global Clinical Trials Review, H2, 2021” clinical trials have been added to the ResearchAndMarkets offering.

The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides prominent drugs for in-progress trials (based on a number of ongoing trials).

The report enhances the decision-making capabilities and helps to create an effective counter-strategies to gain a competitive advantage.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with the reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to Buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Key Topics Covered:

  • Report Guidance
  • The Publisher’s Clinical Trials Report Coverage
  • Clinical Trials by Region
  • Clinical Trials and Average Enrollment by Country
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
  • Top Five Countries Contributing to Clinical Trials in Europe
  • Top Countries Contributing to Clinical Trials in North America
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
  • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Alopecia to Dermatology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Alopecia to Dermatology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
  • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
  • Top Companies Participating in Alopecia Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profile Snapshots
  • Appendix

Companies Mentioned

  • Pfizer Inc
  • Concert Pharmaceuticals Inc
  • Johnson & Johnson
  • AbbVie Inc
  • Aclaris Therapeutics Inc
  • Cosmo Pharmaceuticals NV
  • Dr. Reddy’s Laboratories Ltd
  • Almirall SA
  • Applied Biology Inc
  • GlaxoSmithKline Plc

For more information about this clinical trials report visit https://www.researchandmarkets.com

Global Alopecia Clinical Trials Review

Source

Recent Posts

Celluma RESTORE for Hair Loss

Celluma RESTORE for Hair Loss

BioPhotas Announces Celluma RESTORE for Hair Loss

BioPhotas, Inc., the market leader in therapeutic LED Light Therapy devices announced today a major product line extension to the Company’s award-winning Celluma SERIES of Light Therapy Devices.

The all-in-one Celluma RESTORE is the first LED device FDA-cleared for over-the-counter (OTC) use to treat three common concerns of the mature individual in a single device: hair loss, ageing skin, and general pain conditions. This is the 14th model in the Celluma SERIES.

The all-in-one Celluma RESTORE is the first LED device FDA-cleared for over-the-counter (OTC) use to treat three common concerns of the mature individual in a single device: hair loss, ageing skin, and general pain conditions.

Commenting on the latest addition to the product line, BioPhotas President and Chief Executive Officer Patrick Johnson said, “It’s great to add a Hair Restoration indication-for-use to our long list of treatment clearances from the FDA. Providing a single device that treats whole body aches and pains, fine lines and wrinkles, and hair loss on the scalp is the ultimate baby-boomer anti-ageing device.

Now the mature individual interested in feeling and looking great, and retaining their youthful appearance, can have a device at home that meets all of their rejuvenating needs.” The Celluma RESTORE is targeted directly at the multi-billion-dollar global health and wellness market, specifically, the non-invasive hair restoration segment of the medical aesthetics industry.

The Celluma RESTORE is non-toxic, non-invasive, and painless. The device is versatile, convenient, and easy-to-use in both a clinical setting or at home. Celluma’s patented, the shape-taking design permits customized placement over the head to effectively deliver light energy and promote hair regrowth.

Additionally, the Celluma RESTORE can be placed anywhere on the body to reduce pain and improve skin health. Measuring 16″ x 8″ overall with a treatment area of 14″ x 6″, the Celluma RESTORE can be stored flat in a drawer for convenience and easy access.

Commenting further on the announcement, Mr Johnson said, “Having just celebrated the 10th anniversary of BioPhotas, it is only appropriate that we receive our 10th indication-for-use clearance from the FDA. The Celluma SERIES now has more regulatory credentials than any other LED device in the world and is legally registered for sale in 78 countries around the globe.

We anticipate that the new RESTORE will be available to our U.S. customers in mid-August. The new device is already slated for MDR Tech File review later this summer and should be available in the E.U. and U.K. in the 4th quarter.”

The Celluma SERIES has also continued its winning ways by adding five new industry awards in the first half of 2021. Celluma Light Therapy was recognized by Les Nouvelles Esthetiques & Spa Magazine with two Best Product awards. Dermascope Magazine also recognized Celluma devices with two Aesthetician’s Choice Awards. And the readers of Skin Deep Magazine awarded Celluma the Reader’s Choice award for Favorite LED Device, making the Celluma SERIES the most award-winning LED device with more than 40 international awards.

Visit www.celluma.com to see the complete line of Celluma devices.

About BioPhotas, Inc.

In providing unique devices founded on NASA-developed technology and backed by clinical studies, BioPhotas is bringing to market safe, effective and affordable devices that unlock the clinical power of biophotonics. BioPhotas develops and markets devices for healthcare providers and consumers that conveniently treat a variety of skin, muscle and joint conditions.

BioPhotas Announces Celluma RESTORE for Hair Loss

Source

Recent Posts

Gene Tied to Balding

Gene Tied to Balding

Gene Tied to Balding May Also Raise COVID Risks for Men

It’s long been known that COVID-19 is more fatal for men than women, and new research links some of that excess risk to a gene known to cause a form of hair loss in males.

A U.S. team of researchers first suspected the link when they noticed that men with a common form of hormone-sensitive hair loss, known as androgenetic alopecia, were also more prone to being hospitalized with COVID-19.

“Among hospitalized men with COVID-19, 79% presented with androgenetic alopecia compared to 31%-53% that would be expected in a similarly aged match population,” said researchers led by Dr Andy Goren, chief medical officer at Applied Biology Inc. in Irvine, Calif. They presented their findings May 6 at the virtual spring meeting of the European Academy of Dermatology and Venereology (EADV).

The researchers noted that androgenetic alopecia is caused by the activity of the androgen receptor (AR) gene, which in some men can lead to hair loss. An enzyme called TMPRSS2, the key to COVID-19 infection, is also androgen-sensitive, and might be affected by the AR gene as well, Goren’s group explained.

One key segment on the AR gene appears to affect both COVID-19 severity and the propensity of men to lose their hair due to androgenetic alopecia.

In the new study, the Irvine group conducted a genetic analysis of 65 men hospitalized with COVID-19. They found that men with certain structural differences in the AR gene were more likely to develop severe COVID-19. Speaking in a meeting press release, Goren said the AR gene aberration “could be used as a biomarker to help identify male COVID-19 patients most at risk for ICU admissions.”

He also believes that “the identification of a biomarker connected with the androgen receptor is another piece of evidence highlighting the important role of androgens [male hormones] in COVID-19 disease severity.”

Dr. Teresa Murray Amato is chair of emergency medicine at Long Island Jewish Forest Hills in New York City and has seen many severe cases of COVID-19. She wasn’t connected to the new research, but said it “did show a significant correlation between a higher number of androgen receptors and a higher incidence of ICU admissions for patients infected with COVID-19.”

Amato added, “While the study is small and the exact association is not completely understood, it may show at least one answer to why men were more likely to be admitted to ICU and have overall higher morality with COVID-19 infections.”

According to Amato, more research is needed to determine whether “medications that block androgen receptors will be useful in treating a subset of [COVID-19] patients.”

Because the findings were presented at a medical meeting, they should be considered preliminary until published in a peer-reviewed journal.

Gene Tied to Balding May Also Raise COVID Risks for Men

Source

Recent Posts

MicroRNA That Shows Promise for Hair Regrowth

MicroRNA That Shows Promise for Hair Regrowth

Researchers Identify MicroRNA That Shows Promise for Hair Regrowth

Researchers from North Carolina State University have identified a microRNA (miRNA) that could promote hair regeneration. This miRNA – miR-218-5p – plays an important role in regulating the pathway involved in follicle regeneration and could be a candidate for future drug development.

Hair growth depends on the health of dermal papillae (DP) cells, which regulate the hair follicle growth cycle. Current treatments for hair loss can be costly and ineffective, ranging from invasive surgery to chemical treatments that don’t produce the desired result.

Recent hair loss research indicates that hair follicles don’t disappear where balding occurs, they just shrink. If DP cells could be replenished at those sites, the thinking goes, then the follicles might recover.

A research team led by Ke Cheng, Randall B. Terry, Jr. Distinguished Professor in Regenerative Medicine at NC State’s College of Veterinary Medicine and professor in the NC State/UNC Joint Department of Biomedical Engineering, cultured DP cells both alone (2D) and in a 3D spheroid environment. A spheroid is a three-dimensional cellular structure that effectively recreates a cell’s natural microenvironment.

In a mouse model of hair regeneration, Cheng looked at how quickly hair regrew on mice treated with 2D cultured DP cells, 3D spheroid-cultured DP cells in a keratin scaffolding, and the commercial hair loss treatment Minoxidil. In a 20-day trial, mice treated with the 3D DP cells had regained 90% of hair coverage at 15 days.

“The 3D cells in a keratin scaffold performed best, as the spheroid mimics the hair microenvironment and the keratin scaffold acts as an anchor to keep them at the site where they are needed,” Cheng says. “But we were also interested in how DP cells regulate the follicle growth process, so we looked at the exosomes, specifically, exosomal miRNAs from that microenvironment.” Exosomes are tiny sacs secreted by cells that play an important role in cell to cell communication. Those sacs contain miRNAs.

MiRNAs are small molecules that regulate gene expression. Cheng and his team measured miRNAs in exosomes derived from both 3D and 2D DP cells. In the 3D DP cell-derived exosomes, they pinpointed miR-218-5p, a miRNA that enhances the molecular pathway responsible for promoting hair follicle growth. They found that increasing miR-218-5p promoted hair follicle growth, while inhibiting it caused the follicles to lose function.

“Cell therapy with the 3D cells could be an effective treatment for baldness, but you have to grow, expand, preserve and inject those cells into the area,” Cheng says. “MiRNAs, on the other hand, can be utilized in small molecule-based drugs. So potentially you could create a cream or lotion that has a similar effect with many fewer problems. Future studies will focus on using just this miRNA to promote hair growth.”

The research appears in Science Advances, and was supported by the National Institutes of Health and the American Heart Association. Cheng is corresponding author. Postdoctoral researcher Shiqi Hu is first author.

-peake-

“Dermal exosomes containing miR-218-5p promote hair regeneration by regulating β-catenin signaling”

DOI: 10.1126/sciadv.aba1685

Authors: Shiqi Hu, Zhenhua Li, Halle Lutz, Teng Su, Ke Cheng, North Carolina State University College of Veterinary Medicine and the NC State/UNC Joint Department of Biomedical Engineering; Ke Huang, Jhon Cores, Phuong-Uyen Cao Dinh, North Carolina State University College of Veterinary Medicine

Published: July 24, in Science Advances

Abstract: The progression in the hair follicle cycle from the telogen to the anagen phase is the key to regulating hair regrowth. Dermal papilla (DP) cells support hair growth and regulate the hair cycle. However, they gradually lose key inductive properties upon culture. DP cells can partially restore their capacity to promote hair regrowth after being subjected to spheroid culture. In this study, results revealed that DP spheroids are effective at inducing the progression of the hair follicle cycle from telogen to anagen compared with just DP cell or minoxidil treatment.

Because of the importance of paracrine signaling in this process, secretome and exosomes were isolated from DP cell culture, and their therapeutic efficacies were investigated. We demonstrated that miR-218-5p was notably up-regulated in DP spheroid–derived exosomes. Western blot and immunofluorescence imaging were used to demonstrate that DP spheroid–derived exosomes down-regulated the secreted frizzled-related protein 2 and up-regulated β-catenin, promoting the development of hair follicles.

Researchers Identify MicroRNA That Shows Promise for Hair Regrowth

Source

Recent Posts

Hair Products Cause Hair Loss

Hair Products Cause Hair Loss

Johnson & Johnson Hair Products Cause Hair Loss, Lawsuit Claims

A class-action lawsuit has been filed against Johnson & Johnson with the claim that the company’s OGX hair care products cause significant hair loss.

The products are sold at major national retailers, including Target, Ulta, CVS, Walmart, and Walgreens. Johnson & Johnson shampoos, conditioners, and some hair oils are among the products named in the lawsuit.

The plaintiff, Larissa Whipple, an Illinois woman, cites the ingredient DMDM hydantoin as the main concern. DMDM hydantoin is a preservative and antimicrobial agent sometimes found in hair care products. It’s considered a “formaldehyde donor,” meaning it releases a small amount of formaldehyde overtime to keep the product fresh.

But formaldehyde donors like this one have been linked to allergies, rashes, hair loss, and cancer. The Department of Health and Human Services’ National Toxicology Program has said formaldehyde is known to cause cancer.

The lawsuit says that the company may have violated consumer protection laws by advertising the products containing this ingredient to people who want healthy hair.

“Johnson & Johnson made a number of affirmative misrepresentations … that the products ‘deeply nourish’, ‘gently cleanse,’ and ‘repair hair.’ However, the products’ formula contains an ingredient, or combination of ingredients, that has caused Plaintiff and thousands of consumers to experience hair loss and/or scalp irritation,” the lawsuit says.

Johnson & Johnson says all their ingredients are carefully selected and are listed on the products’ label. The company stated that none of their new products contains DMDM hydantoin and they have not launched any new hair products with this ingredient in several years.

“We carefully select ingredients to ensure the safety and performance of our products,” Johnson & Johnson said in a statement to WebMD. “Some of our existing products contain a small amount of DMDM hydantoin, which is used to prevent mould from developing while the product is in the shower. Every preservative used in our products must clear our rigorous safety assessment process.”

In August 2012, Johnson & Johnson announced it would remove DMDM hydantoin and other similar ingredients from their products by 2015. However, the lawsuit says that is a “broken promise.”

“Johnson & Johnson did in fact remove DMDM hydantoin from existing consumer products at that time,” the lawsuit says. “However, when Johnson & Johnson acquired Vogue International, including their line of OGX products, Johnson & Johnson failed to change the ingredient profile of the products that did not maintain the same standards for consumer safety.”

In the preservatives section of Johnson & Johnson’s safety and care commitment website, the company claims DMDM hydantoin does not meet their safety standards, but further down the page they say they use DMDM hydantoin in products when other preservatives are incompatible with other ingredients in a formula.

Dermatologist Shani Francis, MD, says hair product manufacturers should be striving to create a positive experience for their customers.

“Hair breakage and texture changes are important clues to pay attention to regarding overall hair health. We should always seek out products to enhance our hair care experience,” Francis says. “Having a great understanding of your individual hair needs is most important to avoid problems.”

DMDM hydantoin is listed by the FDA as one of the preservatives found to cause the most allergic reactions from the use of cosmetic products. The FDA requires certain products to list ingredients, but some ingredients may not be specifically identified and instead listed as “fragrance” or “perfume.”

Francis says an important thing to remember is that there is no “one size fits all” for hair care products and seeking out products with a company history of strong customer experience is a good way to look for new products.

“For ingredients, water-based products are generally a good place to start. Aloe vera high in the ingredient list suggests a more acidic pH. Glycerin also is a humectant that can help naturally add moisture to the hair,” Francis says. “Ultimately, balance is most important. Often[times], too much of a good thing is not a good thing. Additionally, if you have an underlying medical, scalp or skin condition, you could have a unique situation and should seek the help of a board-certified dermatologist.”

Johnson & Johnson Hair Products Cause Hair Loss, Lawsuit Claims

Source

Recent Posts

Scalp Microneedling Market

Scalp Microneedling Market

2021-2027 Global Scalp Microneedling Market Report – Production and Consumption Professional Analysis (Impact of COVID-19)

Description_

This report elaborates the market size, market characteristics, and market growth of the Scalp Microneedling industry, and breaks it down according to the type, application, and consumption area of Scalp Microneedling.

The report also conducted a PESTEL analysis of the industry to study the main influencing factors and entry barriers of the industry.

In Chapter 3.4 of the report, the impact of the COVID-19 outbreak on the industry was fully assessed. Fully risk assessment and industry recommendations were made for Scalp Microneedling in a special period. This chapter also compares the markets of Pre COVID-19 and Post COVID-19.

In addition, chapters 8-12 consider the impact of COVID-19 on the regional economy.

Key players in the global Scalp Microneedling market covered in Chapter 13

Lotus
Yonghe Hair Transplant
zcalp

In Chapter 6, on the basis of types, the Scalp Microneedling market from 2015 to 2025 is primarily split into:

Under 0.25 mm
25mm-0.3mm
75mm-1.0mm
1.0mm-1.5mm
Above 1.5mm

In Chapter 7, on the basis of applications, the Scalp Microneedling market from 2015 to 2025 covers:

Hair Transplant
Boost Hair
Others

Geographically, the detailed analysis of production, trade of the following countries is covered in Chapter 4.2, 5

United States
Europe
China
Japan
India

Geographically, the detailed analysis of consumption, revenue, market share and growth rate of the following regions are covered in Chapters 8, 9, 10, 11, 12

North America (Covered in Chapter 8)
United States
Canada
Mexico
Europe (Covered in Chapter 9)

The Middle East and Africa (Covered in Chapter 11)

Years considered for this report:

Historical Years: 2015-2019
Base Year: 2019
Estimated Year: 2020
Forecast Period: 2020-2025

2021-2027 Global Scalp Microneedling Market Report – Production and Consumption Professional Analysis (Impact of COVID-19)

Source

Recent Posts

Radical New Way to Treat Baldness

Radical New Way to Treat Baldness

Hair Follicles Can Smell Sandalwood, And It Could Be a Radical New Way to Treat Baldness

We tend to imagine smells as things that just float around us in the air, but there’s more to it than that.

What we perceive as the smell is actually an intersection between molecules called odorants (or aroma compounds) and olfactory receptors that are expressed by cells in our body, which send a signal to the brain when activated.

That whole process, in a nutshell, is the smell. But it turns out it’s not just our noses that can do it.

New research shows that human hair follicles express an olfactory receptor of their own called OR2AT4, and when OR2AT4 comes into contact with the molecular structure of a specific scent –synthetic sandalwood, as it turns out – it stimulates hair growth.

In other words, your hair – or rather your hair follicles – can ‘smell’, and if they sniff out the right chemical, it could be a radical new way of preventing hair loss.

“This is actually a rather amazing finding,” senior researcher and dermatologist Ralf Paus from the University of Manchester in the UK told The Independent.

“This is the first time ever that it has been shown that the remodelling of a normal human mini-organ [a hair] can be regulated by a simple, cosmetically widely-used odorant.”

Scientists already knew that OR2AT4 could be leveraged to promote keratinocyte proliferation in the skin (which promotes wound healing), leading Paus and his team to wonder whether olfactory receptors could be manipulated to also boost hair growth.

To find out, the researchers took samples of human scalp skin – donated by patients undergoing face-lift operations – and treated them with an application of synthetic sandalwood (aka Sandalore) in the lab.

Unlike authentic sandalwood, which doesn’t bind to OR2AT4, the team found synthetic sandalwood – used in personal care products to provide a sandalwood scent – does bind with the receptor, regulating expression and secretion of a key hair growth-promoting factor called IGF–1.

In other words, by promoting IGF–1, synthetic sandalwood stimulates the growing phase of hair cells, while helping to prevent them from dying.

When another chemical called Phenirat was mixed in to silence OR2AT4, it inhibited hair growing, suggesting the receptor plays a bigger part in hair growth than scientists previously knew.

The research was funded in part by an Italian pharmaceutical company that sells Sandalore in its products – which is something to bear in mind in light of the results.

But because of this pre-existing commercial availability of synthetic sandalwood, the team thinks their “olfactotherapy” discovery could end up helping patients sooner rather than later, if further clinical trials pan out.

According to Paus, the early signs of ongoing research are promising.

“A very small, short and preliminary clinical pilot study performed by an independent CRO [contract research organisation] in 20 female volunteers with topical Sandalore has already suggested a reduction of daily hair loss,” he says.

The next step is to see if that result can be replicated in a larger clinical trial, which the researchers hope to conclude in January next year.

We can’t get too carried away until we see what future tests bring, but according to Nicola Clayton of the British Association of Dermatologists, the initial data look exciting.

“It is a fascinating concept that the human hair follicle, as the authors put it, can ‘smell’ by utilising an olfactory receptor,” she told The Independent.

We’ll have to wait to see where this research leads from here, but if the team’s next trial is a success, we could be looking at an important new mechanism for hair loss prevention here.

Hair Follicles Can ‘Smell’ Sandalwood, And It Could Be a Radical New Way to Treat Baldness

Source

Recent Posts

Top Hair Restoration Surgeon

Top Hair Restoration Surgeon

World’s Leading Hair Transplant Surgeon Dr Alan J. Bauman Receives “#1 Top Hair Restoration Surgeon” and “Top Hair Restoration Surgeon of the Decade” in the Aesthetic Everything® Awards

Alan J. Bauman, MD, ABHRS, IAHRS, FISHRS was named “#1 Top Hair Restoration Surgeon” for the fifth consecutive year and “Top Hair Restoration Surgeon of the Decade” in the annual Aesthetic Everything® Awards.

World’s Leading Hair Transplant Surgeon Dr Alan J. Bauman Receives “#1 Top Hair Restoration Surgeon” and “Top Hair Restoration Surgeon of the Decade” in the Aesthetic Everything® Awards

His win in the Aesthetic and Cosmetic Medicine Awards is the most recent accolade of many earned by Dr Bauman. A full-time hair restoration physician and hair transplant surgeon, he is one of only some 200 physicians worldwide to achieve certification from the American and International Board of Hair Restoration Surgery. He is the first-ever hair transplant surgeon to be formally accepted as an Intercoiffure America Industry Partner, and amongst the elite surgeons accepted by the International Alliance of Hair Restoration Surgeons.

“For almost 25 years, I have devoted my practice to pioneering hair restoration procedures that improve the lives of those struggling with hair loss. This is our mission and the driving force of Bauman Medical. I’m honoured and humbled to be recognized as a five-time ‘#1 Top Hair Restoration Surgeon’ & ‘Top Hair Restoration Surgeon of the Decade,’ in the Aesthetic Everything® Awards.

I could not have achieved these goals without the devotion and support of my entire team at Bauman Medical. I wish to dedicate these awards to the 30,000 plus patients that have put their trust in me; they are the true inspiration for my work,” stated Dr. Bauman.

Dr Bauman founded Bauman Medical in 1997, a 12,000 sq ft “Hair Hospital” in Boca Raton, Florida. He is known for pioneering numerous technologies in the field of hair restoration, including minimally-invasive FUE Follicular Unit Extraction, VIP|FUETM No-Shave Hair Transplant, Low-Level Laser Therapy, PRP Platelet Rich Plasma, PDOgro™, Eyelash Transplants and others.

Dr Bauman’s compassionate, patient-oriented philosophy and individualized artistic approach to protecting, enhancing, and restoring the health and appearance of the hair and scalp has provided life-changing solutions for thousands of patients. He has treated over 30,000 patients, performed over 10,000 hair transplant procedures, and administered over 8,000 PRP treatments.

To learn more about Dr. Bauman and Bauman Medical, visit https://www.baumanmedical.com

About Aesthetic Everything®

Aesthetic Everything® is the largest network of aesthetic professionals in the world, a promotion source to the aesthetics industry.

World’s Leading Hair Transplant Surgeon Dr Alan J. Bauman Receives “#1 Top Hair Restoration Surgeon” and “Top Hair Restoration Surgeon of the Decade” in the Aesthetic Everything® Awards

Source

Recent Posts

Genetic Test for Hair Loss

Genetic Test for Hair Loss

The First Genetic Test for Hair Loss: Introducing TrichoTest, from Fagron

Fagron North America, a global leader in pharmaceutical compounding, debuts the most advanced genetic test supporting medical practitioners’ assessment and treatment of hair loss in the US: TrichoTest.*

TrichoTest is a genetic test performed on patients’ DNA that analyzes 13 genes and 48 genetic variations related to alopecia, including androgenetic alopecia, alopecia areata, and telogen effluvium. This genetic test is based on state-of-the-art DNA microarray technology and utilizes a patented algorithm to provide a personalized treatment recommendation to medical practitioners from 175 million therapeutic alternatives.

TrichoTest analyzes prostaglandins metabolism, inflammation, androgenic effect, vasodilation and blood circulation, collagen synthesis, vitamins and minerals metabolism, and insulin-like growth factor metabolism.

Introducing the most advanced genetic test supporting assessment and treatment of hair loss: TrichoTest, by Fagron.

Alopecia is a progressive and multifactorial condition related to endogenous and exogenous factors. Often, endogenous factors are genetics and are associated with gene expression. The most common type of hair loss, known as androgenetic alopecia, is hereditary. If left untreated, hair loss usually progresses over time.

TrichoTest is the most complete genetic test for alopecia, analyzing genetic factors and other relevant patient characteristics.

TrichoTest supports treatment efficacy. The test results can help medical practitioners develop a personalized treatment plan for their patients, which may include compounded topical solutions, oral supplements, and prescription hair care products.

Today, TrichoTest is the only complete genetic test for alopecia and hereditary hair loss in the US market.

About Fagron North America
Fagron North America (NA), a top-tier pharmaceutical supplier, is focused on creating the future of personalized medicine through investments in genomics, technology, pharmacy essentials and 503B outsourcing.

Fagron Inc., a Fagron NA brand, produces high-quality, innovative pharmaceutical raw materials, equipment, and supplies to prepare personalized medication in the pharmacy. Fagron Inc. offers a broad product portfolio across oral and topical compounding ingredients. As a global leader in pharmaceutical compounding, Fagron supports patient-focused medication that works to improve quality of life.

*TrichoTest is not approved by the Food and Drug Administration and is not intended to diagnose, treat, cure or prevent disease. Any recommendations given to the requesting medical practitioner are for informational purposes only and no individual is required to use any products mentioned in a report.

The First Genetic Test for Hair Loss: Introducing TrichoTest, from Fagron

Source

Recent Posts

Stem Cell and Platelet Rich Plasma (PRP) Alopecia

Stem Cell and Platelet Rich Plasma Alopecia

2021-2027 Global and Regional Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies

The research team projects that the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market size will grow from XXX in 2020 to XXX by 2027, at an estimated CAGR of XX. The base year considered for the study is 2020, and the market size is projected from 2020 to 2027.

The prime objective of this report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing with 10 major regions and 50 major countries.

Deep researches and analysis were done during the preparation of the report. The readers will find this report very helpful in understanding the market in depth. The data and the information regarding the market are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the industry experts.

The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better.

By Market Players:

Orange County Hair Restoration Center
Colorado Surgical Center & Hair Institute
Evolution Hair Loss Institute
Hair Sciences Center of Colorado
Hair Transplant Institute of Miami
Anderson Center for Hair
Virginia Surgical Center
Savola Aesthetic Dermatology Center

By Type

Platelet Rich Plasma Injections
Stem Cell Therapy

By Application

Dermatology Clinics
Hospitals

By Regions/Countries:

North America
United States
Canada
Mexico
East Asia
China
Japan
South Korea
Europe
Germany
United Kingdom
France
Italy
Russia
Spain
Netherlands
Switzerland
Poland
South Asia
India
Pakistan
Bangladesh
Southeast Asia
Indonesia
Thailand
Singapore
Malaysia
Philippines
Vietnam
Myanmar
Middle East
Turkey
Saudi Arabia
Iran
United Arab Emirates
Israel
Iraq
Qatar
Kuwait
Oman
Africa
Nigeria
South Africa
Egypt
Algeria
Morocoo
Oceania
Australia
New Zealand
South America
Brazil
Argentina
Colombia
Chile
Venezuela
Peru
Puerto Rico
Ecuador
Rest of the World
Kazakhstan

Points Covered in The Report

The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.

The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analyzed 12 years of data history and forecast.

The growth factors of the market is discussed in detail wherein the different end users of the market are explained in detail.

Data and information by market player, by region, by type, by application and etc, and custom research can be added according to specific requirements.

The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Key Reasons to Purchase

To gain insightful analyses of the market and have a comprehensive understanding of the global market and its commercial landscape.

Assess the production processes, major issues, and solutions to mitigate the development risk.

To understand the most affecting driving and restraining forces in the market and their impact on the global market.

Learn about the market strategies that are being adopted by leading respective organizations.

To understand the future outlook and prospects for the market.

Besides the standard structure reports, we also provide custom research according to specific requirements.

The report focuses on Global, Top 10 Regions and Top 50 Countries Market Size of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies 2016-2021, and development forecast 2022-2027 including industries, major players/suppliers worldwide and market share by regions, with the company and product introduction, position in the market including their market status and development trend by types and applications which will provide its price and profit status, and marketing status & market growth drivers and challenges, with the base year as 2020.

Key Indicators Analysed

Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2021 & Sales by Product Types.

Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2022-2027. Further the report provides break down details about each region & countries covered in the report.

Identifying its production, consumption, import & export, sales volume & revenue forecast.

Market Analysis by Product Type: The report covers the majority of Product Types in the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Industry, including its product specifications by each key player, volume, sales by Volume and Value (M USD).

Market Analysis by Application Type: Based on the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Industry and its applications, the market is further sub-segmented into several major Applications of its industry. It provides you with the market size, CAGR & forecast by each industry application.

Market Trends: Market key trends include Increased Competition and Continuous Innovations.

Opportunities and Drivers: Identifying the Growing Demands and New Technology

Porters Five Force Analysis:

The report will provide the state of competition in the industry depends on five basic forces: the threat of new entrants, bargaining power of suppliers, bargaining power of buyers, the threat of substitute products or services, and existing industry rivalry.

COVID-19 Impact

The report covers Impact of Coronavirus COVID-19: Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency.

The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market in 2021. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor/outdoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

2021-2027 Global and Regional Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies

Source

Recent Posts